Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future

Article Article scientifique Article Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future eng 2017 author Darwich A S author Ogungbenro K author Vinks A A author Powell J R author Reny J-L author Marsousi Niloufar 599218 author Daali Youssef 46042 author Fairman D author Cook James 747113 author Lesko L J author McCune J S author Knibbe Caj author de Wildt S N author Leeder J S author Neely M author Zuppa A F author Vicini P author Aarons L author Johnson T N author Boiani J author Rostami-Hodjegan A 646-656 10.1002/cpt.659 28182269 0009-9236 Patient groups prone to polypharmacy and special subpopulations are susceptible to suboptimal treatment. Refined dosing in special populations is imperative to improve therapeutic response and/or lowering the risk of toxicity. Model-informed precision dosing (MIPD) may improve treatment outcomes by achieving the optimal dose for an individual patient. There is, however, relatively little published evidence of large-scale utility and impact of MIPD, where it is often implemented as local collaborative efforts between academia and healthcare. This article highlights some successful applications of bringing MIPD to clinical care and proposes strategies for wider integration in healthcare. Considerations are brought up herein that will need addressing to see MIPD become "widespread clinical practice," among those, wider interdisciplinary collaborations and the necessity for further evidence-based efficacy and cost-benefit analysis of MIPD in healthcare. The implications of MIPD on regulatory policies and pharmaceutical development are also discussed as part of the roadmap. Cost-Benefit Analysis Delivery of Health Care Integrated Forecasting Humans Models Biological Pharmaceutical Preparations/administration & dosage Precision Medicine/trends Dewey 615 Dewey 617 31 Section des sciences pharmaceutiques 17 63 Département d'anesthésiologie, pharmacologie, soins intensifs et urgences 229 false 302 Groupe Desmeules Jules (pharmacologie/toxicologie) 567 1280 Pharmaco-omiques et médecine de précision 1003 Clinical Pharmacology and Therapeutics 101 5 c3554eaa-d6bf-45f6-bce8-7df04e0938fa Article (Published version) Restricted cpt659.pdf 1699043 application/pdf restrictedAccess Faculté des sciences / Section des sciences pharmaceutiques Faculté de médecine / Section de médecine clinique / Département d'anesthésiologie, pharmacologie, soins intensifs et urgences

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future	Clinical Pharmacology and Therapeutics			2017	604	0

Archive ouverte UNIGE

Cook, James